HIV-1 capsid mutants inhibit the replication of wild-type virus at both early and late infection phases.
In-frame mutations were introduced into various portions of the human immunodeficiency virus type 1 (HIV-1) gag gene, and potentials of the mutants to suppress the replication of wild-type HIV-1 were monitored. In contrast to results obtained with matrix and nucleocapsid mutants, almost all capsid mutants blocked HIV-1 replication completely in single-round replication assays. A capsid mutant designated C6b was demonstrated to be one of the most efficient inhibitors for HIV-1 reported to date, and to be effective at both early and late viral replication phases. T-cells, which are engineered to express the C6b Gag in response to HIV-1 infection, were perfectly resistant to HIV-1.
Furuta
R A
RA
Institute for Virus Research, Kyoto University, Japan.
Shimano
R
R
Ogasawara
T
T
Inubushi
R
R
Amano
K
K
Akari
H
H
Hatanaka
M
M
Kawamura
M
M
Adachi
A
A
D015153:Blotting, Western; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D002213:Capsid / Q000737:chemistry / Q000235:genetics* / Q000502:physiology; D015500:Chloramphenicol O-Acetyltransferase / Q000235:genetics / Q000378:metabolism; D015870:Gene Expression; D015683:Gene Products, gag / Q000235:genetics / Q000502:physiology*; D015750:Genes, gag; D005822:Genetic Vectors; D015497:HIV-1 / Q000235:genetics* / Q000502:physiology*; D006801:Humans; D016296:Mutagenesis; D009154:Mutation; D014162:Transfection; D014407:Tumor Cells, Cultured; D014779:Virus Replication
D015683:Gene Products, gag; D015500:Chloramphenicol O-Acetyltransferase